New data presented at the 2022 American Society of Hematology (ASH) Meeting show the use of mitapivat is beneficial for patients with a pyruvate kinase (PK) deficiency. PK deficiency is a rare, hereditary hemolytic anemia caused by a single gene defect encoding the red blood cell-specific form of PK. The condition is often associated with acute and long-term complications, as well as a spectrum of signs and symptoms including jaundice, fatigue, and dyspnea. Source: MDMag To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.

read more